HeartBeam, a medical technology company focused on cardiac care, announced a commercial partnership with ClearCardio, a preventive cardiology practice. This agreement represents HeartBeam's first commercial customer and includes a planned investment from ClearCardio, indicating strategic alignment between the companies.
The partnership involves integrating HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention program for arrhythmia assessment. This integration will enable patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system. The technology is designed to deliver actionable heart intelligence outside traditional medical facilities.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software receiving clearance in December 2025. The company holds over 20 issued patents related to technology enablement. This platform technology creates the first-ever cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG.
The agreement is structured as a Letter of Intent outlining subscription-based commercial terms and a collaborative deployment plan. This staged rollout supports HeartBeam's broader growth strategy, including expansion into concierge care and preventive cardiology networks. The company continues development of its 12-lead ECG patch monitor and advancement of AI-driven cardiac care initiatives.
This partnership matters because it represents a significant step toward making advanced cardiac monitoring more accessible outside clinical settings. By enabling patients to capture clinical-grade ECG readings at home, the technology could help identify cardiac health trends and acute conditions earlier, potentially directing patients to appropriate care more quickly. The integration into ClearCardio's preventive cardiology program serving thousands of patients demonstrates practical application of remote cardiac monitoring technology.
The implications extend beyond this specific partnership. Successful implementation could accelerate adoption of remote cardiac monitoring technologies across healthcare systems, potentially reducing hospital visits for routine monitoring while improving early detection of cardiac issues. As healthcare continues shifting toward preventive models and remote patient monitoring, technologies like HeartBeam's 3D ECG system could become increasingly important for managing cardiac health.
For more information about HeartBeam, visit https://ibn.fm/BEAT. Additional details about the partnership are available in the full press release at https://ibn.fm/EDyjd. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
